Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Saved in:
| Title: | Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. |
|---|---|
| Authors: | Bissonnette, R.1 rbissonnette@innovaderm.ca, Luger, T.2, Thaçi, D.3, Toth, D.4, Messina, I.5, You, R.6, Guana, A.5, Fox, T.7, Papavassilis, C.7, Gilloteau, I.7, Mrowietz, U.8 |
| Source: | British Journal of Dermatology. Oct2017, Vol. 177 Issue 4, p1033-1042. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 125802059 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Bissonnette%2C+R%2E%22">Bissonnette, R.</searchLink><relatesTo>1</relatesTo><i> rbissonnette@innovaderm.ca</i><br /><searchLink fieldCode="AR" term="%22Luger%2C+T%2E%22">Luger, T.</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Thaçi%2C+D%2E%22">Thaçi, D.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Toth%2C+D%2E%22">Toth, D.</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Messina%2C+I%2E%22">Messina, I.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22You%2C+R%2E%22">You, R.</searchLink><relatesTo>6</relatesTo><br /><searchLink fieldCode="AR" term="%22Guana%2C+A%2E%22">Guana, A.</searchLink><relatesTo>5</relatesTo><br /><searchLink fieldCode="AR" term="%22Fox%2C+T%2E%22">Fox, T.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Papavassilis%2C+C%2E%22">Papavassilis, C.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Gilloteau%2C+I%2E%22">Gilloteau, I.</searchLink><relatesTo>7</relatesTo><br /><searchLink fieldCode="AR" term="%22Mrowietz%2C+U%2E%22">Mrowietz, U.</searchLink><relatesTo>8</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22British+Journal+of+Dermatology%22">British Journal of Dermatology</searchLink>. Oct2017, Vol. 177 Issue 4, p1033-1042. 10p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=125802059 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1111/bjd.15706 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 10 StartPage: 1033 Titles: – TitleFull: Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bissonnette, R. – PersonEntity: Name: NameFull: Luger, T. – PersonEntity: Name: NameFull: Thaçi, D. – PersonEntity: Name: NameFull: Toth, D. – PersonEntity: Name: NameFull: Messina, I. – PersonEntity: Name: NameFull: You, R. – PersonEntity: Name: NameFull: Guana, A. – PersonEntity: Name: NameFull: Fox, T. – PersonEntity: Name: NameFull: Papavassilis, C. – PersonEntity: Name: NameFull: Gilloteau, I. – PersonEntity: Name: NameFull: Mrowietz, U. IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 10 Text: Oct2017 Type: published Y: 2017 Identifiers: – Type: issn-print Value: 00070963 Numbering: – Type: volume Value: 177 – Type: issue Value: 4 Titles: – TitleFull: British Journal of Dermatology Type: main |
| ResultId | 1 |
